{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T00:20:41Z","timestamp":1793060441859,"version":"4.5.0"},"reference-count":184,"publisher":"Informa UK Limited","issue":"11","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Safety"],"published-print":{"date-parts":[[2023,11,2]]},"DOI":"10.1080\/14740338.2023.2274420","type":"journal-article","created":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T15:43:55Z","timestamp":1698767035000},"page":"1049-1071","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":8,"title":["A safety review of recently approved and emerging drugs for patients with relapsed or refractory multiple myeloma"],"prefix":"10.1080","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4948-5507","authenticated-orcid":false,"given":"Shonali","family":"Midha","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Center for Multiple Myeloma Research, Harvard Medical School, Boston, MA, USA"},{"name":"Division of Hematology, Brigham and Women\u2019s Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7277-0061","authenticated-orcid":false,"given":"Monique A.","family":"Hartley-Brown","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Center for Multiple Myeloma Research, Harvard Medical School, Boston, MA, USA"},{"name":"Division of Hematology, Brigham and Women\u2019s Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clifton C.","family":"Mo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Center for Multiple Myeloma Research, Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrier","family":"Hossain","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Center for Multiple Myeloma Research, Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Nadeem","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Center for Multiple Myeloma Research, Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth K.","family":"O\u2019Donnell","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Center for Multiple Myeloma Research, Harvard Medical School, Boston, MA, USA"},{"name":"Division of Hematology, Brigham and Women\u2019s Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giada","family":"Bianchi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Center for Multiple Myeloma Research, Harvard Medical School, Boston, MA, USA"},{"name":"Division of Hematology, Brigham and Women\u2019s Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9369-4413","authenticated-orcid":false,"given":"Adam S.","family":"Sperling","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Center for Multiple Myeloma Research, Harvard Medical School, Boston, MA, USA"},{"name":"Division of Hematology, Brigham and Women\u2019s Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob P.","family":"Laubach","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Center for Multiple Myeloma Research, Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7426-8865","authenticated-orcid":false,"given":"Paul G.","family":"Richardson","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Center for Multiple Myeloma Research, Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,11,10]]},"reference":[{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21763"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.07.039"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.2196\/39068"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2023.03.005"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1020011"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00695-5"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0141-0"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14514"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2018.0002"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0002"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.014"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26590"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13092018"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI129205"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01234-2"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.606368"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0198-4"},{"key":"e_1_3_6_20_1","unstructured":"sanofi-aventis U.S. LLC. SARCLISA (isatuximab-irfc) injection for intravenous use - prescribing information. [cited 2023 Feb 21]. Available at: https:\/\/products.sanofi.us\/Sarclisa\/sarclisa.pdf"},{"key":"e_1_3_6_21_1","unstructured":"Sanofi Winthrop Industrie. Sarclisa - summary of product characteristics. [cited Feb 21]. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/sarclisa-epar-product-information_en.pdf"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32556-5"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00019-5"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00592-4"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.04.013"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30788-0"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33809"},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-164877"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.8018"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.8017"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-139332"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-160445"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18479"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac574"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1597"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.18.00143"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.8025"},{"key":"e_1_3_6_38_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.253450"},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3038"},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26319"},{"key":"e_1_3_6_41_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-0568"},{"key":"e_1_3_6_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13835"},{"key":"e_1_3_6_43_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.279229"},{"key":"e_1_3_6_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26602"},{"key":"e_1_3_6_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.11.005"},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17499"},{"key":"e_1_3_6_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0868-z"},{"key":"e_1_3_6_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2021.106576"},{"key":"e_1_3_6_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01262-w"},{"key":"e_1_3_6_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0857-2"},{"key":"e_1_3_6_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00478-4"},{"key":"e_1_3_6_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14657"},{"key":"e_1_3_6_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008209"},{"key":"e_1_3_6_54_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-740787"},{"key":"e_1_3_6_55_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-02-895193"},{"key":"e_1_3_6_56_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000738"},{"key":"e_1_3_6_57_1","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2022.2082725"},{"key":"e_1_3_6_58_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33448"},{"key":"e_1_3_6_59_1","unstructured":"GlaxoSmithKline. BLENREP (belantamab mafodotin-blmf) for injection for intravenous use. [cited 2023 Feb 22]. Available at: https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Blenrep\/pdf\/BLENREP-PI-MG.PDF"},{"key":"e_1_3_6_60_1","unstructured":"GlaxoSmithKline. BLENREP summary of product characteristics. [cited Feb 22 2023]. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/blenrep-epar-product-information_en.pdf"},{"key":"e_1_3_6_61_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00369-0"},{"key":"e_1_3_6_62_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-020-00280-8"},{"key":"e_1_3_6_63_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00494-4"},{"key":"e_1_3_6_64_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2015.0064"},{"key":"e_1_3_6_65_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0618"},{"key":"e_1_3_6_66_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2409"},{"key":"e_1_3_6_67_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000829628.48136.02"},{"key":"e_1_3_6_68_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.678634"},{"key":"e_1_3_6_69_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.235937"},{"key":"e_1_3_6_70_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26728"},{"key":"e_1_3_6_71_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00592-3"},{"key":"e_1_3_6_72_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-022-00212-5"},{"key":"e_1_3_6_73_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1026251"},{"key":"e_1_3_6_74_1","doi-asserted-by":"publisher","DOI":"10.1097\/ICL.0000000000000768"},{"key":"e_1_3_6_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2022.101392"},{"key":"e_1_3_6_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.07.047"},{"key":"e_1_3_6_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2022.06.009"},{"key":"e_1_3_6_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2021.101133"},{"key":"e_1_3_6_79_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18298"},{"key":"e_1_3_6_80_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01884-7"},{"key":"e_1_3_6_81_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0734-z"},{"key":"e_1_3_6_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01338-6"},{"key":"e_1_3_6_83_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478"},{"key":"e_1_3_6_84_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-166494"},{"key":"e_1_3_6_85_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159969"},{"key":"e_1_3_6_86_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204591"},{"key":"e_1_3_6_87_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159707"},{"key":"e_1_3_6_88_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-157988"},{"key":"e_1_3_6_89_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-147983"},{"key":"e_1_3_6_90_1","unstructured":"Janssen Biotech Inc. TECVAYLI (teclistamab-cqyv) injection for subcutaneous use. [cited 19 Jan 2023]. Available at: https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/TECVAYLI-pi.pdf"},{"key":"e_1_3_6_91_1","unstructured":"Janssen-Cilag International NV. TECVAYLI summary of product characteristics. [cited 2023 Mar 3]. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tecvayli-epar-product-information_en.pdf"},{"key":"e_1_3_6_92_1","unstructured":"Pfizer Inc. ELREXFIO (elranatamab-bcmm) injection for subcutaneous use. [cited 2023 21 Aug]. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761345s000lbl.pdf"},{"key":"e_1_3_6_93_1","unstructured":"Janssen Biotech Inc. TALVEY (talquetamab-tgvs) injection for subcutaneous use. [cited 2023 Aug 21]. Available at: https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/TALVEY-pi.pdf"},{"key":"e_1_3_6_94_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159009"},{"key":"e_1_3_6_95_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-167008"},{"key":"e_1_3_6_96_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1032775"},{"key":"e_1_3_6_97_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159711"},{"key":"e_1_3_6_98_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.8032"},{"key":"e_1_3_6_99_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02528-9"},{"key":"e_1_3_6_100_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-162738"},{"key":"e_1_3_6_101_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01504"},{"key":"e_1_3_6_102_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-163192"},{"key":"e_1_3_6_103_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-122895"},{"key":"e_1_3_6_104_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000843624.82943.92"},{"key":"e_1_3_6_105_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"e_1_3_6_106_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-162469"},{"key":"e_1_3_6_107_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213614"},{"key":"e_1_3_6_108_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8"},{"key":"e_1_3_6_109_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-146060"},{"key":"e_1_3_6_110_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-146072"},{"key":"e_1_3_6_111_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159169"},{"key":"e_1_3_6_112_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303379"},{"key":"e_1_3_6_113_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2209900"},{"key":"e_1_3_6_114_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"e_1_3_6_115_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-169971"},{"key":"e_1_3_6_116_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159381"},{"key":"e_1_3_6_117_1","doi-asserted-by":"publisher","DOI":"10.1177\/10781552221140320"},{"key":"e_1_3_6_118_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.02.008"},{"key":"e_1_3_6_119_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00775-w"},{"key":"e_1_3_6_120_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009435"},{"key":"e_1_3_6_121_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02197"},{"key":"e_1_3_6_122_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00808-8"},{"key":"e_1_3_6_123_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006178"},{"key":"e_1_3_6_124_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010539"},{"key":"e_1_3_6_125_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-163733"},{"key":"e_1_3_6_126_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau7746"},{"key":"e_1_3_6_127_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2022.11.013"},{"key":"e_1_3_6_128_1","first-page":"NS","volume-title":"International Myeloma Society 6th Annual Nursing Symposium","author":"Aronson E","unstructured":"Aronson E Characterization and management of oral and dermatological toxicities in patients receiving the CD3 X GPRC5D bispecific antibody talquetamab for the treatment of relapsed\/refractory multiple myeloma. International Myeloma Society 6th Annual Nursing Symposium; Los Angeles, CA2022. p. NS\u2013001."},{"key":"e_1_3_6_129_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.8033"},{"key":"e_1_3_6_130_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-162555"},{"key":"e_1_3_6_131_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-1090"},{"key":"e_1_3_6_132_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9113577"},{"key":"e_1_3_6_133_1","unstructured":"Bristol-Myers Squibb Company. ABECMA (idecabtagene vicleucel) suspension for intravenous infusion. [cited 19 Jan 2023]. Available at: https:\/\/packageinserts.bms.com\/pi\/pi_abecma.pdf"},{"key":"e_1_3_6_134_1","unstructured":"Bristol-Myers Squibb Pharma EEIG. ABECMA (idecabtagene vicleucel) summary of product characteristics. [cited Feb 23 2023]. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/abecma-epar-product-information_en.pdf"},{"key":"e_1_3_6_135_1","unstructured":"Janssen Biotech Inc. CARVYKTI (ciltacabtagene autoleucel) suspension for intravenous infusion. [Last accessed 19 Jan 2023]. Available at: https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/CARVYKTI-pi.pdf"},{"key":"e_1_3_6_136_1","unstructured":"Janssen Pharmaceuticals Inc. CARVYKTI (ciltacabtagene autoleucel) summary of product characteristics. [Last accessed Feb 23 2023]. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/carvykti-epar-product-information_en.pdf"},{"key":"e_1_3_6_137_1","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-22-0018"},{"key":"e_1_3_6_138_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.148"},{"key":"e_1_3_6_139_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00629-1"},{"key":"e_1_3_6_140_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01564-7"},{"key":"e_1_3_6_141_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1697814"},{"key":"e_1_3_6_142_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00754-1"},{"key":"e_1_3_6_143_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00741-2"},{"key":"e_1_3_6_144_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-162682"},{"key":"e_1_3_6_145_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.5207"},{"key":"e_1_3_6_146_1","unstructured":"Karyopharm Therapeutics Inc. XPOVIO (selinexor) tablets for oral use US prescribing information. [cited Feb 23 2023]. Available at: https:\/\/www.karyopharm.com\/wp-content\/uploads\/2019\/07\/NDA-212306-SN-0071-Prescribing-Information-01July2019.pdf"},{"key":"e_1_3_6_147_1","unstructured":"Stemline Therapeutics BV NEXPOVIO (selinexor) summary of product characteristics. [Last accessed Feb 23 2023]. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/nexpovio-epar-product-information_en.pdf"},{"key":"e_1_3_6_148_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903455"},{"key":"e_1_3_6_149_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-06-858852"},{"key":"e_1_3_6_150_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32292-3"},{"key":"e_1_3_6_151_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02259"},{"key":"e_1_3_6_152_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00381-1"},{"key":"e_1_3_6_153_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30525-8"},{"key":"e_1_3_6_154_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-163809"},{"key":"e_1_3_6_155_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020004146"},{"key":"e_1_3_6_156_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0756-6"},{"key":"e_1_3_6_157_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.12.026"},{"key":"e_1_3_6_158_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.01.014"},{"key":"e_1_3_6_159_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-11-752840"},{"key":"e_1_3_6_160_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.07.014"},{"key":"e_1_3_6_161_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26172"},{"key":"e_1_3_6_162_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26434"},{"key":"e_1_3_6_163_1","unstructured":"Oncopeptides Inc. PEPAXTO (melphalan flufenamide) for injection for intravenous use: prescribing information. [Last accessed Mar 6 2023].Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/214383s000lbl.pdf"},{"key":"e_1_3_6_164_1","unstructured":"Oncopeptides AB. Pepaxti: EPAR - Production information. [Last accessed Mar 6 2023]. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/pepaxti-epar-production-information_en.pdf"},{"key":"e_1_3_6_165_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30044-2"},{"key":"e_1_3_6_166_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13205210"},{"key":"e_1_3_6_167_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.716751"},{"key":"e_1_3_6_168_1","unstructured":"AbbVie Inc. VENCLEXTA (venetoclax tablets) for oral use. Prescribing Information. [Last accessed Feb 23 2023]. Available at: https:\/\/www.rxabbvie.com\/pdf\/venclexta.pdf"},{"key":"e_1_3_6_169_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-157945"},{"key":"e_1_3_6_170_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00290-3"},{"key":"e_1_3_6_171_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-158180"},{"issue":"2","key":"e_1_3_6_172_1","first-page":"S187","article-title":"Iberdomide in combination with dexamethasone and daratumumab, bortezomib, or carfilzomib in patients with relapsed\/refractory multiple myeloma","volume":"5","author":"Lonial S","year":"2021","unstructured":"Lonial S, Richardson PG, Popat R, et al. Iberdomide in combination with dexamethasone and daratumumab, bortezomib, or carfilzomib in patients with relapsed\/refractory multiple myeloma. Hemasphere. 2021;5(suppl 2):S187.","journal-title":"Hemasphere"},{"key":"e_1_3_6_173_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(22)00326-3"},{"key":"e_1_3_6_174_1","unstructured":"AbbVie. Venclyxto summary of product characteristics. [Last accessed Feb 23 2023]. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/venclyxto-epar-product-information_en.pdf"},{"key":"e_1_3_6_175_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.346"},{"key":"e_1_3_6_176_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16889"},{"key":"e_1_3_6_177_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.7112"},{"key":"e_1_3_6_178_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0001"},{"key":"e_1_3_6_179_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00717-2"},{"key":"e_1_3_6_180_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0637"},{"key":"e_1_3_6_181_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02182-7"},{"key":"e_1_3_6_182_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2021.1972802"},{"key":"e_1_3_6_183_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-162253"},{"key":"e_1_3_6_184_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032645"},{"key":"e_1_3_6_185_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2022.109168"},{"key":"e_1_3_6_186_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf2341"}],"container-title":["Expert Opinion on Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14740338.2023.2274420","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T10:52:26Z","timestamp":1707994346000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14740338.2023.2274420"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,2]]},"references-count":184,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11,2]]}},"alternative-id":["10.1080\/14740338.2023.2274420"],"URL":"https:\/\/doi.org\/10.1080\/14740338.2023.2274420","relation":{},"ISSN":["1474-0338","1744-764X"],"issn-type":[{"value":"1474-0338","type":"print"},{"value":"1744-764X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-05-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}